Search Results - "Gonsalves, Wilson I"

The New Oral Anticoagulants in Clinical Practice by Gonsalves, Wilson I., MD, Pruthi, Rajiv K., MBBS, Patnaik, Mrinal M., MBBS

“…Abstract Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for decades. However, with the US Food and Drug…”
Get full text

Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity by Kurmi, Kiran, Hitosugi, Sadae, Wiese, Elizabeth K., Boakye-Agyeman, Felix, Gonsalves, Wilson I., Lou, Zhenkun, Karnitz, Larry M., Goetz, Matthew P., Hitosugi, Taro

“…Lysine succinylation was recently identified as a post-translational modification in cells. However, the molecular mechanism underlying lysine succinylation…”
Get full text

Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time by Sidiqi, M Hasib, Aljama, Mohammed A, Buadi, Francis K, Warsame, Rahma M, Lacy, Martha Q, Dispenzieri, Angela, Dingli, David, Gonsalves, Wilson I, Kumar, Shaji, Kapoor, Prashant, Kourelis, Taxiarchis, Hogan, William J, Gertz, Morie A

“…Purpose Autologous stem-cell transplantation (ASCT) has been used in patients with immunoglobulin light chain (AL) amyloidosis for more than two decades. Early…”
Get full text

Bispecific antibody targets and therapies in multiple myeloma by Rees, Matthew, Abdallah, Nadine, Yohannan, Binoy, Gonsalves, Wilson I

“…Recently, several bispecific antibodies (BsAbs) have been approved for the treatment of relapsed multiple myeloma (MM) after early phase trials in heavily…”
Get full text

Ageism in the t(11;14) Subtype of Multiple Myeloma by Gonsalves, Wilson I, Parmar, Harsh

Get more information

Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147 by GONSALVES, Wilson I, MAHONEY, Michelle R, HUBBARD, Joleen M, CHAN, Emily, NAIR, Suresh, BERENBERG, Jeffrey L, MCWILLIAMS, Robert R, SARGENT, Daniel J, NELSON, Garth D, ALBERTS, Steven R, SINICROPE, Frank A, GOLDBERG, Richard M, LIMBURG, Paul J, THIBODEAU, Stephen N, GROTHEY, Axel

“…KRAS and BRAF (V600E) mutations are important predictive and prognostic markers, respectively, in colon cancer, but little is known about patient and clinical…”
Get full text

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria by Lakshman, Arjun, Rajkumar, S. Vincent, Buadi, Francis K., Binder, Moritz, Gertz, Morie A., Lacy, Martha Q., Dispenzieri, Angela, Dingli, David, Fonder, Amie L., Hayman, Suzanne R., Hobbs, Miriam A., Gonsalves, Wilson I., Hwa, Yi Lisa, Kapoor, Prashant, Leung, Nelson, Go, Ronald S., Lin, Yi, Kourelis, Taxiarchis V., Warsame, Rahma, Lust, John A., Russell, Stephen J., Zeldenrust, Steven R., Kyle, Robert A., Kumar, Shaji K.

“…In 2014, the International Myeloma Working Group reclassified patients with smoldering multiple myeloma (SMM) and bone marrow-plasma cell percentage (BMPC%) ≥…”
Get full text

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma by Ramakrishnan, Vijay G, Miller, Kevin C, Macon, Elaine P, Kimlinger, Teresa K, Haug, Jessica, Kumar, Sanjay, Gonsalves, Wilson I, Rajkumar, S Vincent, Kumar, Shaji K

“…Despite recent advances in the treatment of multiple myeloma, patients with this disease still inevitably relapse and become refractory to existing therapies…”
Get full text

Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma by Gonsalves, Wilson I., Broniowska, Katarzyna, Jessen, Erik, Petterson, Xuan-Mai, Bush, Alexander Graham, Gransee, Jaimee, Lacy, Martha Q., Hitosugi, Taro, Kumar, Shaji K.

“…Oncogenic drivers of progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) such as c-MYC have downstream effects on…”
Get full text

Sarcopenia identified by computed tomography imaging using a deep learning–based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma by Nandakumar, Bharat, Baffour, Francis, Abdallah, Nadine H., Kumar, Shaji K., Dispenzieri, Angela, Buadi, Francis K., Dingli, David, Lacy, Martha Q., Hayman, Suzanne R., Kapoor, Prashant, Leung, Nelson, Fonder, Amie, Hobbs, Miriam, Hwa, Yi Lisa, Muchtar, Eli, Warsame, Rahma, Kourelis, Taxiarchis V., Go, Ronald S., Kyle, Robert A., Gertz, Morie A., Rajkumar, S. Vincent, Klug, Jason, Korfiatis, Panagiotis, Gonsalves, Wilson I.

“…Background Sarcopenia increases with age and is associated with poor survival outcomes in patients with cancer. By using a deep learning–based segmentation…”
Get full text

Effects of Volume and Site of Blood Draw on Blood Culture Results by Gonsalves, Wilson I, Cornish, Nancy, Moore, Michael, Chen, Aimin, Varman, Meera

“…Blood culture contamination greatly affects clinical decisions. Hence, it is of interest to assess the influence of factors such as the volume of blood drawn…”
Get full text

Evolving progress in the management of malignant plasma cell disorders by Atilgan, Ezgi, Gonsalves, Wilson I.

Get full text

Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma by Ravi, Gayathri, Gonsalves, Wilson I.

“…•The diagnostic and treatment paradigms in multiple myeloma have evolved over the last two decades.•Various prognostic features have been delineated to risk…”
Get full text

Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma by Lakshman, Arjun, Singh, Preet Paul, Rajkumar, S. Vincent, Dispenzieri, Angela, Lacy, Martha Q., Gertz, Morie A., Buadi, Francis K., Dingli, David, Hwa, Yi Lisa, Fonder, Amie L., Hobbs, Miriam, Hayman, Suzanne R., Zeldenrust, Steven R., Lust, John A., Russell, Stephen J., Leung, Nelson, Kapoor, Prashant, Go, Ronald S., Lin, Yi, Gonsalves, Wilson I., Kourelis, Taxiarchis, Warsame, Rahma, Kyle, Robert A., Kumar, Shaji K.

“…Experience with intensive chemotherapy for relapsed/refractory multiple myeloma (RRMM) using VDT PACE regimen and its modifications (VDT PACE‐like regimens:…”
Get full text

Enzymatic activation of pyruvate kinase increases cytosolic oxaloacetate to inhibit the Warburg effect by Wiese, Elizabeth K., Hitosugi, Sadae, Loa, Sharon T., Sreedhar, Annapoorna, Andres-Beck, Lindsey G., Kurmi, Kiran, Pang, Yuan-Ping, Karnitz, Larry M., Gonsalves, Wilson I., Hitosugi, Taro

“…Pharmacological activation of the glycolytic enzyme PKM2 or expression of the constitutively active PKM1 isoform in cancer cells results in decreased lactate…”
Get full text

Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance by Lakshman, Arjun, Paul, Shilpa, Rajkumar, S. Vincent, Ketterling, Rhett P., Greipp, Patricia T., Dispenzieri, Angela, Gertz, Morie A, Buadi, Francis K., Lacy, Martha Q., Dingli, David, Fonder, Amie L., Hayman, Suzanne R., Hobbs, Miriam A., Gonsalves, Wilson I., Hwa, Yi Lisa, Kapoor, Prashant, Leung, Nelson, Go, Ronald S., Lin, Yi, Kourelis, Taxiarchis V., Warsame, Rahma, Lust, John A., Russell, Stephen J., Zeldenrust, Steven R., Kyle, Robert A., Kumar, Shaji K.

Get full text

Induction therapy pre‐autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation by Hwa, Yi L., Kumar, Shaji K., Gertz, Morie A., Lacy, Martha Q., Buadi, Francis K., Kourelis, Taxiarchis V., Gonsalves, Wilson I., Rajkumar, S. Vincent, Go, Ronald S., Leung, Nelson, Kapoor, Prashant, Dingli, David, Kyle, Robert A., Russell, Stephen, lust, John A., Hayman, Suzanne R., Lin, Yi, Zeldenrust, Steven, Dispenzieri, Angela

“…There is no consensus on whether patients with immunoglobulin light chain amyloidosis (AL) should receive induction therapy prior to an autologous stem cell…”
Get full text

The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow up by Abdallah, Nadine, Dispenzieri, Angela, Muchtar, Eli, Buadi, Francis K., Kapoor, Prashant, Lacy, Martha Q., Hwa, Yi L., Fonder, Amie, Hobbs, Miriam A., Hayman, Suzanne R., Leung, Nelson, Dingli, David, Go, Ronald S., Lin, Yi, Gonsalves, Wilson I., Binder, Moritz, Kourelis, Taxiarchis, Warsame, Rahma, Kyle, Robert A., Rajkumar, S. Vincent, Gertz, Morie A., Kumar, Shaji K.

“…The current treatment paradigm of AL amyloidosis lacks effective fibril-directed therapies. Doxycycline has been shown to have anti-fibril properties in…”
Get full text

Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients by Al Saleh, Abdullah S., Parmar, Harsh V., Visram, Alissa, Muchtar, Eli, Buadi, Francis K., Go, Ronald S., Dispenzieri, Angela, Kapoor, Prashant, Warsame, Rahma, Lacy, Martha Q., Dingli, David, Leung, Nelson, Gonsalves, Wilson I., Kourelis, Taxiarchis V., Gertz, Morie A., Kyle, Robert A., Rajkumar, S. Vincent, Kumar, Shaji K.

“…Previous reports have suggested that a higher bone marrow plasma-cell percentage (BMPC%) is associated with worse outcomes. However, it is unknown whether…”
Get full text

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma by Goel, Utkarsh, Charalampous, Charalampos, Kapoor, Prashant, Binder, Moritz, Buadi, Francis K., Dingli, David, Dispenzieri, Angela, Fonder, Amie, Gertz, Morie A., Gonsalves, Wilson I., Hayman, Suzanne R., Hobbs, Miriam A., Hwa, Yi L., Kourelis, Taxiarchis, Lacy, Martha Q., Leung, Nelson, Lin, Yi, Warsame, Rahma M., Kyle, Robert A., Rajkumar, S. Vincent, Kumar, Shaji K.

Get full text